Abstract
Background:
Sleep apnea leads to cognitive impairment in older patients, but its association with neurodegeneration remains controversial, and most studies do not distinguish between the more common obstructive form (OSAS) and the rarer central form (CSAS).
Objective:
The purpose of this study was to assess the prevalence of the different forms of sleep apnea in a cohort of cognitively impaired elderly patients (>70 years) and to investigate their associations with cognitive deficit, weighted against known risk factors for neurodegeneration.
Methods:
Overnight polygraphy was performed for 76 consecutive patients admitted to our geriatric unit. Their cognitive function was assessed using the Mini Mental-State Exam (MMSE), Mattis Dementia Rating Scale (MDRS) and Stroop test. Multivariable analyses were performed to determine associations between cognitive function and independent variables describing demographics, sleep apnea measures, and cardiovascular risk factors.
Results:
The cohort comprised 58 women and 18 men aged a mean of 84 years (range, 73–96). Sleep apnea syndrome (SAS) was diagnosed in 48 patients (63%), of which 31 (41%) with OSAS and 17 (22%) with CSAS. Multivariable regression analysis revealed that MDRS was lower in patients with OSAS (β = −10.03, p = 0.018), that Stroop Colors and Words delays increased with AHI (β = 0.17, p = 0.030 and β = 0.31, p = 0.047) and that that Stroop Interference delay was higher in patients with CSAS (β = 24.45, p = 0.002).
Conclusion:
Sleep apnea is thus highly prevalent in elderly patients with cognitive impairment. OSAS was associated with lower general cognitive function, while CSAS was only associated with increased Stroop Interference delays. Elderly patients with cognitive deficit could benefit from sleep apnea screening and treatment.
Introduction
Sleep apnea syndrome (SAS) is a disorder characterized by repeated pauses in breathing during sleep (). It is often underdiagnosed (), though its prevalence is increasing and was recently shown to be up to 40% in the general population (), and likely higher in the elderly population (; ). SAS interrupts sleep and causes intermittent hypoxia () which could contribute to a range of pathophysiological consequences, including cognitive impairment (; ), particularly in older patients (; ; ). In fact, SAS is more prevalent in patients suffering from neurodegenerative diseases (; ) and is suspected to increase risks of developing Alzheimer’s disease (; ; ).
The association between SAS and neurodegenerative diseases remains controversial (; ) and the pathophysiological consequences of SAS are still unclear (; ; ; ). This is further complicated by the fact that most studies do not distinguish between the more common obstructive form (OSAS), characterized by recurrent collapse of the upper respiratory tract, and the rarer central form (CSAS), characterized by repetitive pauses in breathing without respiratory effort. Moreover, the causes of cognitive impairments are difficult to establish in patients over 70 years old, who often exhibit multiple co-morbidities.
Validated modifiable risk factors can be used to mitigate the progression of age-related cognitive decline. For instance, OSAS is associated with Alzheimer’s disease biomarker accumulation () and can be treated with continuous positive airway pressure (CPAP) (; ; ; ), which improves cognitive function in patients suffering from Alzheimer’s disease, although its effect on pathological progression remains unknown (; ; ). The purpose of this exploratory study was therefore to (a) assess the prevalence of each form of SAS in a cohort of elderly patients (>70 years old) admitted to our geriatric unit for non-acute reasons, and (b) investigate the independent relation between sleep apnea and cognitive performance, measured using validated tests, including the Mini Mental-State Exam (MMSE), the Mattis Dementia rating Scale (MDRS) and the Stroop test, and competing against known risk factors for cognitive impairment. The hypothesis was that (i) the prevalence of SAS in elderly patients consulting for cognitive deficit would be greater than that reported for the general population and (ii) elderly patients with SAS would have significantly worse MMSE, MDRS and Stroop test scores, independently of confounding factors.
Materials and Methods
We enrolled 115 consecutive patients admitted to our geriatric unit for non-acute reasons (non-emergency, no surgery, no mandatory overnight stay) between October 2015 and March 2018. The inclusion criterion was patients aged over 70 years. The exclusion criteria were (i) refusal to undergo sleep apnea diagnosis with overnight polygraph recording (26 patients), or (ii) refusal or inability to complete neurocognitive assessment using structural cerebral magnetic resonance imaging (MRI) (12 patients). In addition, 1 patient died before completing the cognitive assessment, which left a study cohort of 76 patients (Figure 1), who underwent overnight ambulatory polygraphy (Weinmann SOMNOlab 2, Hamburg, Germany) to measure their Apnea-Hypopnea Index (AHI), total number of events per night, mean arterial blood oxygen saturation (SaO2) and sleep time at SaO2 below 90% (). Apnea severity was noted based on the AHI, as mild (AHI 5–15), moderate (AHI 16–30), or severe (AHI > 30). Apneas were defined as cessation of airflow for at least 10 s and hypopneas were defined as a reduction of airflow to ≤50% of baseline for at least 10 s (). The final diagnosis of sleep apnea, obstructive (OSAS) or central (CSAS) was determined by a pulmonologist (YD) based on the relative number of obstructive or central events per night, based on the definition by : obstructive sleep apnea is characterized by ongoing ventilatory effort while central sleep apnea is characterized by withdrawal of central respiratory drive. OSAS and CSAS were defined when a patient had 5 or more episodes of obstructive or central apneas per hour of sleep, respectively.
FIGURE 1
The patient’s overall cognitive function was assessed by clinical psychologists (IG and ASM) using the following validated scores: (a) Mini-Mental State Examination (MMSE) (), which ranges from 0 to 30 points. Patients scoring ≤23 considered cognitively impaired. (b) MDRS, which comprises five subscales, spanning the areas of attention, initiation-perseveration, construction, conceptualization and memory (; ). () Stroop Colors and Words test was used to assess attention and executive functioning (), which are known to be affected by sleep apnea (; ; ). The Colors test asks patients to recognize the color of dots that appear for a short time, while the Words test asks them to read words (names of colors) that appear for a short time. The Interference test requires the patients to read the words (names of colors) written in different (wrong) colors and repress the wrong answer (Stroop interference effect). For all tests, the delay before the answer, and the number of uncorrected mistakes, are reported. () Montgomery-Asberg Depression rating scale [MADRS ()], on 60 points, and Goldberg anxiety scale () on nine points, to rule out effects of depression or anxiety on cognitive test results.
Final etiological diagnosis of cognitive impairment was based on the neurocognitive assessments, as well as MRI (Siemens Avanto 27780, Munich, Germany) results and history of geriatric consultations. Mild cognitive impairment was diagnosed following the criteria of , while Alzheimer’s disease (AD) and AD-like diseases were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) and the recommendations of the National Institute on Aging – Alzheimer’s Association workgroups ().
Vascular risk factors for the development of AD () were diagnosed based on a comprehensive assessment performed in our geriatric unit. Blood samples were obtained after a minimum of 10 h of fasting. The diagnosis of vitamin D [25(OH)D3] deficiency was given if blood measurements were below 30 ng/mL, diabetes was diagnosed with blood glucose levels above 7 mmol/L and anemia with hemoglobin levels below 12 (women) or 13 (men) g/dL. Likewise, the reference range was 4.1–6.5 mmol/L for total cholesterol and 0.6–1.8 mmol/L for triglycerides. Inflammation was diagnosed if the blood levels of C-reactive protein (CRP) was higher than 10 mg/L () as per the recommendations of the World Health Organization (), and leucocyte concentration was higher than 100000/mm3. The blood pressure of patients was measured during waking hours, and after polygraphy, during night-time hours.
Written informed consent was obtained from all patients for their participation and confirmed by their next-of-kin if necessary. The study protocol was approved by an independent Ethical Review Board (CPP Amiens: 2015/6) and the national Data Protection Authority (CNIL:150075B-31). The study was registered in clinicaltrials.gov (NCT02578303). All procedures were performed in accordance with the 1964 Helsinki declaration.
Statistical Analysis
Descriptive statistics were used to summarize the data. Shapiro–Wilk tests were used to assess the normality of distributions. Due to skewed distribution of continuous variables, the data was presented as median [IQR]. Univariable regressions were performed to determine associations between five outcomes (MMSE, MDRS and Stroop Colors, Words, and Interference tests) and seventeen independent variables (age, BMI, sex, diagnosis of SAS, OSAS, or CSAS, AHI, sleep apnea severity, blood oxygen saturation, sleep time with hypoxia, number of events per night, diabetes, inflammation, hypercholesterolemia, hypertriglyceridemia, vitamin D deficiency, and anemia). Variables that do not measure sleep apnea were included because they represent cardiovascular risk factors known to affect sleep apnea or cognition in elderly patients (). Multivariable regressions were then performed after backward selection (criterion p < 0.15). Hypercholesterolemia was excluded from the multivariable models due to a low incidence (n < 10) in our cohort. Sample size of 47 patients was calculated to be sufficient to show even the moderate negative correlation between the MDRS and the AHI with 80% power and 5% significance. Therefore, our sample size of 76 was deemed sufficient for analysis, considering a probably high failure rate in the neurocognitive tests due to the age of the patients. Statistical analyses were performed using R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria). P-values < 0.05 were considered statistically significant.
Results
The final cohort comprised 58 women (76%) and 18 men (24%), aged 84 [IQR, 80–88] years (range, 73–96), with BMI 24 [IQR, 21–27] kg/m2 (range, 15.6–40) (Table 1). Overall, they were not depressed (MADRS:6, IQR, 3–11; range, 0–31) nor anxious (Goldberg:3, IQR, 1–5; range, 0–9). A number of patients presented comorbidities, including heart failure (11.8%), aortic stenosis (3.9%), mitral stenosis (1.3%), carotid stenosis (3.9%), cerebral hematoma (3.9%), transient ischemic accident (3.9%), and cancer (25%). The prevalence of arterial hypertension was 32% while awake but rose to 59% while asleep. Thirty-three patients (43%) had mild cognitive impairment, 9 (12%) had vascular dementia, 7 (9%) had Alzheimer’s disease, 1 (1%) had Lewy-body dementia, and 26 (34%) had mixed dementia.
TABLE 1
| Cohort (n = 76) | |||
| Median | [IQR] | (Range) | |
| Age (years) | 84 | [80–88] | (73–96) |
| BMI (kg/m2) | 24 | [21–27] | (16–40) |
| Depression (MADRS∗/60) | 6 | [3–11] | (0–31) |
| Anxiety (Goldberg/9) | 3 | [1–5] | (0–9) |
| n | (%) | ||
| Women | 58 | (76%) | |
| Diabetes | 10 | (13%) | |
| Hypercholesterolemia | 5 | (7%) | |
| Hypertriglyceridemia | 18 | (24%) | |
| Vitamin D deficiency | 40 | (53%) | |
| Anemia | 51 | (67%) | |
| Hypertension (awake) | 23 | (32%) | |
| Hypertension (asleep) | 41 | (59%) | |
| Diagnosis | |||
| Mild cognitive impairment | 33 | (43%) | |
| Vascular dementia | 9 | (12%) | |
| Alzheimer’s disease | 7 | (9%) | |
| Dementia with Lewy bodies | 1 | (1%) | |
| Mixed dementia | 26 | (34%) | |
Patient demographics.
∗Montgomery-Asberg Depression Rating Scale. IQR, Interquartile range.
The median AHI was 16.4 (IQR, 5.4–35.3; range, 0.5–73), and indicated severe sleep apnea in 32 patients (42%) (Table 2). SAS was diagnosed in 48 patients (63%), of which 31 (41%) with OSAS and 17 (22%) with CSAS.
TABLE 2
| Cohort (n = 76) | |||
| Median | [IQR] | (Range) | |
| Blood oxygen saturation (SpO2,%) | 95 | [93–96] | (87–98) |
| Sleep time with hypoxia∗(%) | 2 | [1–7] | (0–54) |
| Number of events per night | 56 | [22–113] | (2–548) |
| Apnea-hypopnea index (AHI) | 16 | [5–35] | (1–73) |
| n | (%) | ||
| SAS severity (AHI) | |||
| None (<5) | 19 | (25%) | |
| Mild (5–15) | 18 | (24%) | |
| Moderate (15–30) | 7 | (9%) | |
| Severe (>30) | 32 | (42%) | |
| Sleep Apnea Syndrome (SAS) | 48 | (63%) | |
| Obstructive | 31 | (41%) | |
| Central | 17 | (22%) | |
Sleep Apnea Syndrome.
∗Hypoxia defined as a reduction of SpO2 by 10%. IQR, Interquartile range.
The median MMSE score was 22.5 (IQR, 19–26; range, 7–30), with 41 (54%) patients scoring ≤23 (Table 3). Univariable regression revealed the MMSE score to be associated with sex and diabetes (Table 4). There was no significant difference in MMSE between patients with moderate to severe SAS and patients with mild to no SAS (Figure 2). Multivariable regression analysis revealed that MMSE decreased with age (β = −0.25, CI, −0.45 to −0.05; p = 0.014) and in patients with diabetes (β = −4.91, CI, −8.10 to −1.72; p = 0.01.
TABLE 3
| Cohort (n = 76) | |||
| Median | [IQR] | (Range) | |
| Mini-mental state exam (MMSE/30) | 23 | [19–26] | (7–30) |
| Mattis dementia rating scale (MDRS/144) | 121 | [109–132] | (60–143) |
| Stroop color and word test | |||
| Colors (delay, s) | 19 | [15–29] | (6–70) |
| Colors (non-corrected mistakes) | 0 | [0–0] | (0–6) |
| Words (delay, s) | 34 | [25–50] | (14–147) |
| Words (non-corrected mistakes) | 0 | [0–1] | (0–9) |
| Interference (delay, s) | 53 | [38–76] | (15–116) |
| Interference (non-corrected mistakes) | 4 | [1–13] | (0–24) |
Cognitive Tests.
IQR, Interquartile range.
TABLE 4
| Univariable | Multivariable (n = 71) Backward selection | |||||
| Regression coefficient | 95% C.I. (range) | p-Value | Regression coefficient | 95% C.I. (range) | p-Value | |
| Age | −0.19 | (−0.39 to 0.02) | 0.072 | −0.25 | (−0.45 to −0.05) | 0.014 |
| BMI (kg/m2) | 0.14 | (−0.09 to 0.37) | 0.226 | |||
| Female Gender | −2.72 | (−5.37 to 0.08) | 0.044 | |||
| SAS | 0.07 | (−2.22 to 2.35) | 0.955 | |||
| OSAS | −0.29 | (−2.58 to 2.00) | 0.801 | |||
| CSAS | 0.92 | (−1.86 to 3.70) | 0.510 | |||
| Apnea-hypopnea index (AHI) | 0.01 | (−0.05 to 0.07) | 0.723 | 0.04 | (−0.01–0.10) | 0.142 |
| Sleep apnea severity | ||||||
| None | REF | |||||
| Mild | 1.11 | (−2.08 to 4.31) | 0.489 | |||
| Moderate | −3.44 | (−7.90 to 1.01) | 0.128 | |||
| Severe | 0.35 | (−2.46 to 3.15) | 0.806 | |||
| Blood oxygen saturation (SpO2,%) | −0.07 | (−0.60 to 0.45) | 0.787 | |||
| Sleep time with hypoxia∗ (%) | 0.01 | (−0.07 to 0.10) | 0.738 | |||
| Number of events per night | 0.00 | (−0.01 to 0.01) | 0.438 | |||
| Diabetes | −4.02 | (−7.30 to −0.73) | 0.017 | −4.91 | (−8.10 to −1.72) | 0.003 |
| Inflammation | 1.96 | (−0.33 to 4.25) | 0.092 | |||
| Hypercholesterolemia∗∗ | −0.83 | (−5.31 to 3.65) | 0.712 | |||
| Hypertriglyceridemia | −0.89 | (−3.58 to 1.79) | 0.508 | |||
| Vitamin D deficiency | 1.17 | (−1.09 to 3.44) | 0.304 | 1.83 | (−0.33 to 4.00) | 0.096 |
| Anemia | 0.17 | (−2.26 to 2.59) | 0.892 | |||
Uni- and Multi-variable regression to identify factors associated with the Mini Mental State Exam (MMSE).
∗Hypoxia defined as a reduction of SpO2 by 10%. ∗∗Excluded from multivariable analysis due to low incidence (<10).
FIGURE 2
The median MDRS score was 120.5 (IQR, 109.3–132.0; range, 60–143) (Table 3). Univariable regression revealed the MDRS to be associated with SAS, OSAS, AHI, diabetes, and hypertriglyceridemia (Table 5). The MDRS score was lower for patients with moderate to severe SAS compared to patients with mild to no SAS (Figure 2; p = 0.009). Multivariable regression analysis revealed that MDRS decreased with age (β = −0.81, CI, −1.54 to −0.08; p = 0.031), in patients with OSAS (β = −10.03, CI, −18.26 to −1.80; p = 0.018), and in patients with diabetes (β = −16.10, CI, −27.8 to −4.36; p = 0.008).
TABLE 5
| Univariable | Multivariable (n = 66) Backward selection | |||||
| Regression coefficient | 95% C.I. (range) | p-Value | Regression coefficient | 95% C.I. (range) | p-Value | |
| Age | −0.74 | (−1.52 to 0.04) | 0.062 | −0.81 | (−1.54 to −0.08) | 0.031 |
| BMI (kg/m2) | 0.14 | (−0.77 to 1.06) | 0.755 | |||
| Female Gender | −9.24 | (−19.09 to 0.61) | 0.066 | |||
| SAS | −8.78 | (−17.50 to −0.05) | 0.049 | |||
| OSAS | −9.94 | (−18.72 to −1.17) | 0.027 | −10.03 | (−18.26 to −1.80) | 0.018 |
| CSAS | 2.74 | (−7.35 to 12.84) | 0.589 | |||
| Apnea-hypopnea index (AHI) | −0.23 | (−0.44 to −0.01) | 0.039 | |||
| Sleep apnea severity | ||||||
| None | REF | |||||
| Mild | 5.50 | (−6.84 to 17.84) | 0.377 | |||
| Moderate | −4.17 | (−20.61 to 12.27) | 0.614 | |||
| Severe | −9.36 | (−20.06 to 1.33) | 0.085 | |||
| Blood Oxygen Saturation (SpO2,%) | 0.83 | (−1.25 to 2.90) | 0.430 | |||
| Sleep time with hypoxia∗ (%) | 0.03 | (−0.29 to 0.35) | 0.865 | |||
| Number of events per Night | 0.01 | (−0.03 to 0.04) | 0.745 | |||
| Diabetes | −13.42 | (−25.87 to −0.97) | 0.035 | −16.10 | (−27.8 to −4.36) | 0.008 |
| Inflammation | 6.35 | (−2.63 to 15.33) | 0.163 | |||
| Hypercholesterolemia∗∗ | −10.83 | (−27.46 to 5.79) | 0.198 | |||
| Hypertriglyceridemia | −9.99 | (−19.91 to −0.07) | 0.048 | |||
| Vitamin D deficiency | 0.07 | (−9.39 to 8.35) | 0.907 | |||
| Anemia | −4.93 | (−14.35 to 4.49) | 0.300 | −4.47 | (−13.13 to 4.19) | 0.306 |
Uni- and Multi-variable regression to identify factors associated with the Mattis Dementia Rating Scale (MDRS).
∗Hypoxia defined as a reduction of SpO2 by 10%. ∗∗Excluded from multivariable analysis due to insufficient number of observations (<10).
Twenty patients were unable to perform the Stroop test. For the remaining patients, the median Stroop Colors delay was 19 s (IQR, 15–29; range, 6–70) and the median number of mistakes was 0 (IQR, 0–0; range, 0–6) (Table 3). The Stroop Words delay was 34 s (IQR, 25–50; range, 14–147) and the median number of mistakes was 0 (IQR, 0–1; range, 0–9). The Stroop Interference delay was 53 s (IQR, 38–76; range, 15–116) and the median number of mistakes was 4 (IQR, 1–13; range, 0–24). Univariable regressions revealed the Stroop Colors delay to be associated with age, AHI, severe SAS, and anemia (Table 6), the Stroop Words delay to be associated with AHI (Table 7), and the Stroop Interference delay to be associated with SAS, CSAS, AHI and diabetes (Table 8). All three delays were increased in patients with moderate to severe SAS compared to patients with mild to no SAS (Figure 3, Color, p = 0.022, Word, p = 0.031, Interference, p = 0.031). Multivariable regressions revealed that Stroop Color delay increased with age (β = 0.64, CI, 0.09–1.19; p = 0.024) and AHI (β = 0.17, CI, 0.02–0.32; p = 0.030), that Stroop Words delay increased with AHI (β = 0.31, CI, 0.00–0.62; p = 0.047) and that Stroop Interference delay increased in patients with CSAS (β = 24.45, CI, 15.21–50.55; p = 0.0024) and in patients with diabetes (β = 32.88, CI, 15.21–50.55; p = 0.001).
TABLE 6
| Univariable | Multivariable (n = 60) Backward selection | |||||
| Regression coefficient | 95% C.I. (range) | p-Value | Regression coefficient | 95% C.I. (range) | p-Value | |
| Age | 0.79 | (0.21–1.36) | 0.008 | 0.64 | (0.09–1.19) | 0.024 |
| BMI (kg/m2) | 0.08 | (−0.67–0.83) | 0.829 | |||
| Female gender | 4.01 | (−3.18–11.20) | 0.269 | |||
| SAS | 4.24 | (−2.35–10.83) | 0.203 | |||
| OSAS | 1.27 | (−5.33–7.87) | 0.702 | |||
| CSAS | 1.55 | (−6.18–9.28) | 0.689 | |||
| Apnea-hypopnea index (AHI) | 0.24 | (0.08–0.40) | 0.003 | 0.17 | (0.02–0.32) | 0.030 |
| Sleep apnea severity | ||||||
| None | REF | |||||
| Mild | 4.31 | (−8.62–17.25) | 0.507 | |||
| Moderate | 3.21 | (−6.17–12.60) | 0.496 | |||
| Severe | 8.38 | (0.20–16.56) | 0.045 | |||
| Blood oxygen saturation (SpO2,%) | −0.47 | (−2.05–1.10) | 0.552 | |||
| Sleep time with hypoxia∗ (%) | −0.03 | (−0.26–0.21) | 0.831 | |||
| Number of events per night | 0.02 | (−0.00–0.05) | 0.063 | |||
| Diabetes | 6.88 | (−2.59–16.34) | 0.151 | 7.91 | (−0.47–16.29) | 0.064 |
| Inflammation | −1.53 | (−8.20–5.14) | 0.648 | |||
| Hypercholesterolemia∗∗ | −5.46 | (−18.68–7.75) | 0.411 | |||
| Hypertriglyceridemia | −0.01 | (−8.09–8.07) | 0.998 | |||
| Vitamin D deficiency | −5.07 | (−11.48–1.35) | 0.119 | |||
| Anemia | 6.93 | (0.22–13.63) | 0.043 | 5.98 | (−0.07–12.04) | 0.053 |
Uni- and Multi-variable regression to identify factors associated with the Stroop Colors Test (delay, s).
∗Hypoxia defined as a reduction of SpO2 by 10%. ∗∗Excluded from multivariable analysis due to low incidence (<10).
TABLE 7
| Univariable | Multivariable (n = 56) Backward selection | |||||
| Regression coefficient | 95% C.I. (range) | p-Value | Regression coefficient | 95% C.I. (range) | p-value | |
| Age | 1.06 | (−0.13–2.25) | 0.081 | |||
| BMI (kg/m2) | 0.70 | (−0.70–2.11) | 0.321 | |||
| Female Gender | 2.33 | (−11.68–16.33) | 0.741 | |||
| SAS | 8.59 | (−4.16–21.35) | 0.182 | |||
| OSAS | 7.23 | (−5.36–19.82) | 0.254 | |||
| CSAS | −2.35 | (−17.34–12.64) | 0.754 | |||
| Apnea-hypopnea index (AHI) | 0.31 | (0.00–0.62) | 0.047 | 0.31 | (0.00–0.62) | 0.047 |
| Sleep apnea severity | ||||||
| None | REF | |||||
| Mild | 15.59 | (−8.58–39.76) | 0.201 | |||
| Moderate | (−13.97–22.54) | 0.640 | ||||
| Severe | 14.59 | (−0.90–30.07) | 0.064 | |||
| Blood oxygen saturation (SpO2,%) | −1.17 | (−4.14–1.80) | 0.433 | |||
| Sleep time with hypoxia∗ (%) | −0.19 | (−0.64–0.26) | 0.393 | |||
| Number of events per Night | 0.04 | (−0.01–0.09) | 0.092 | |||
| Diabetes | 3.51 | (−16.95–23.97) | 0.732 | |||
| Inflammation | −2.20 | (−15.06–10.66) | 0.733 | |||
| Hypercholesterolemia∗∗ | 9.81 | (−14.91–34.53) | 0.429 | |||
| Hypertriglyceridemia | 0.32 | (−15.34–15.99) | 0.967 | |||
| Vitamin D deficiency | −12.08 | (−24.33–0.16) | 0.053 | |||
| Anemia | 0.05 | (−13.33–13.43) | 0.994 | |||
Uni- and Multi-variable regression to identify factors associated with the Stroop Words Test (delay, s).
∗Hypoxia defined as a reduction of SpO2 by 10%. ∗∗Excluded from multivariable analysis due to low incidence (<10).
TABLE 8
| Univariable | Multivariable (n = 50) Backward selection | |||||
| Regression coefficient | 95% C.I. (range) | p-Value | Regression coefficient | 95% C.I. (range) | p-value | |
| Age | 1.29 | (−0.05–2.63) | 0.059 | 1.13 | (−0.05–2.30) | 0.061 |
| BMI (kg/m2) | 0.12 | (−1.41–1.66) | 0.872 | |||
| Female Gender | 5.74 | (−9.76–21.24) | 0.460 | |||
| SAS | 16.93 | (3.21–30.66) | 0.017 | |||
| OSAS | 1.98 | (−12.05–16.01) | 0.778 | 13.57 | (−0.14–27.28) | 0.052 |
| CSAS | 17.18 | (2.02–32.33) | 0.027 | 24.45 | (8.42–40.49) | 0.004 |
| Apnea-hypopnea index (AHI) | 0.45 | (−0.11–0.78) | 0.011 | |||
| Sleep apnea severity | ||||||
| None | REF | |||||
| Mild | –6.02 | (−26.26–14.23) | 0.553 | |||
| Moderate | 7.65 | (−20.32–35.62) | 0.585 | |||
| Severe | 14.15 | (−3.65–31.95) | 0.116 | |||
| Blood Oxygen Saturation (SpO2,%) | –0.33 | (−3.58–2.93) | 0.840 | |||
| Sleep Time with hypoxia∗ (%) | 0.03 | (−0.44–0.51) | 0.890 | |||
| Number of events per Night | 0.04 | (−0.02–0.09) | 0.189 | |||
| Diabetes | 28.53 | (−8.65–48.41) | 0.006 | 32.88 | (15.21–50.55) | 0.001 |
| Inflammation | –0.52 | (−14.80–13.77) | 0.942 | |||
| Hypercholesterolemia∗∗ | –12.64 | (−42.31–17.02) | 0.395 | |||
| Hypertriglyceridemia | 13.97 | (−2.22–30.16) | 0.089 | |||
| Vitamin D deficiency | –6.85 | (−20.71–7.02) | 0.326 | |||
| Anemia | 8.65 | (−5.91–23.21) | 0.238 | |||
Uni- and Multi-variable regression to identify factors associated with the Stroop Interference Test (delay, s).
∗Hypoxia defined as a reduction of SpO2 by 10%. ∗∗Excluded from multivariable analysis due to low incidence (<10).
FIGURE 3
Discussion
The prevalence of SAS in elderly patients admitted to our geriatric unit was 63% (OSAS in 41% and CSAS in 22%), which is considerably higher than that reported in the general population, between 24 and 40% (; ). Our results demonstrated the preeminence of SAS among factors associated with cognitive deficit thus confirming previous observations from the literature (; ; ; ). It is worth noting that the prevalence of SAS in our cohort remains higher than recent estimates for the elderly population (25% for men and 42% for women) (), which could be due to our great proportion of patients with cognitive deficit (; ). Interestingly, this finding is in agreement with recent observations from German geriatric wards (). This study is nevertheless the first to investigate comorbidities associating with SAS while differentiating OSAS and CSAS in this particular population.
The patients in this cohort presented various levels of cognitive deficit, although all were diagnosed with disorders ranging from MCI to AD or vascular dementia. Interestingly, in this diverse cohort, OSAS was identified as an independent predictor of poor MDRS scores but was not associated with MMSE scores. While both tests are used to detect cognitive impairment in the elderly, there are indications that they may not evaluate the same cognitive domains (), or that the MDRS may be more specific and sensitive (; ). Furthermore, the ability of the MMSE to efficiently screen for cognitive impairment in the elderly has recently been put into question (). It is important to note that the fact that CSAS did not affect MDRS scores in our study could be due to its lower incidence in our cohort and is no proof of lack of effect. Our results also revealed that AHI associates with impaired attention, indicated by the increased delay in the Stroop Colors and Words tests, and that CSAS and perhaps OSAS associate with impaired executive function, indicated by the increased delay in the Stroop Interference test. This is in line with the literature reporting that SAS affects vigilance and the attentional domain () and executive function (; ). In 2012, suggested that OSAS may affect vigilance through sleep fragmentation and executive function through hypoxia. In this study, we measured hypoxia and sleep apnea severity (AHI) separately but were not able to verify this hypothesis. It is unclear why, unlike previous literature, AHI rather than oxygen desaturation was associated with cognitive deficit in our cohort, though it could be due to the different manifestations in SAS in the elderly population and in the general population (; ). The relationship between intermittent hypoxia and cognition remain complex, however, and animal studies have suggested that intermittent hypoxia may not directly impair brain structure (), but may play a role in the etiology of Alzheimer’s Disease (; ; ). Nevertheless, fragmented sleep and excessive daytime sleepiness have been shown to modify the relationship between AHI and several co-morbidities (; ) and could contribute to cognitive decline in SAS patients (). Unfortunately, daytime sleepiness was not evaluated in this study, and could therefore not be included in the multivariable model. We found no association between the number of events per night and cognitive outcomes, though this variable may have underestimated sleep fragmentation, as it did not take snoring into account. The interaction between AHI, sleep fragmentation, daytime sleepiness, and cognitive decline in the elderly remains therefore a question for further search.
We decided to use vascular risk factors known to associate with SAS or AD to adjust the regression models for our cognitive tests. Interestingly, only diabetes independently associated with reduced MMSE and MDRS scores, as well as increased Stroop delay. Taken together, OSAS and diabetes are associated with a reduction of 26 points in the MDRS. Interestingly, severe sleep apnea was shown to be associated with diabetes in the general population (). This preeminence of diabetes among risk factors for cognitive deficit has been recently demonstrated () and our results indicate that sleep apnea should be investigated among the other risk factors for the cognitive deficit of the elderly. Indeed, sleep apnea treatment with continuous positive air pressure has shown success in slowing down cognitive decline in the elderly (; ; ), so that sleep apnea could be considered a modifiable risk factor for cognitive decline in the elderly ().
This study is among the first to combine a comprehensive measure of sleep apnea, including the AHI, sleep hypoxia and events per night, with a multivariable regression analysis including known vascular risk factors to determine associations with cognitive deficit in cohort of elderly patients suffering from diffuse cognitive impairment. Moreover, the cohort was controlled for depression and anxiety. The fact that sleep apnea was selected among other well-established risk factors is a powerful demonstration of its association with cognitive deficit in these patients and suggests that sleep apnea ought to be screened for and treated in priority when possible. Further, our distinction of patients suffering primarily from OSAS or CSAS offers novel insight into the effects of these different, yet oftentimes overlapping disorders.
However, this study has several limitations. First, the age of the patients and their cognitive impairment caused a large number of failures of the neurocognitive assessment, especially for the Stroop test. This has weakened our regression analyses and increased the chance of underestimating associations. Second, the fact that patients unable to complete the neurocognitive tests were excluded from the study has created a potential bias, since these patients were likely to exhibit more severe cognitive symptoms. Third, no additional measure of dementia was used to validate MDRS results and assess dementia severity. Fourth, the prevalence of women in our cohort represents the population admitted to our institution, and our results may not be applicable for younger sleep apnea patients, which are predominantly men. Finally, our list of competing risk factors was incomplete, as we were unable to correctly or systematically assess the patients’ smoking habits, alcohol consumption, physical inactivity, or daytime sleepiness.
Conclusion
This study reveals the high prevalence of sleep apnea in elderly patients with cognitive impairment, and demonstrates the independent association between sleep apnea and cognitive deficit. OSAS was associated with a reduction of the MDRS score, while CSAS was associated with an increased Stroop Interference delay. Our data suggest that elderly patients with cognitive deficit should be screened for sleep apnea and encouraged to follow treatments, if necessary, to prevent cognitive decline.
Statements
Data availability statement
The datasets generated for this study are available on request to the corresponding author.
Ethics statement
This work was completed after being approved by an independent Ethical Review Board (CPP Amiens: 2015/6) and the national Data Protection Authority (CNIL:150075B-31). The study was registered in clinicaltrials.gov (NCT02578303) and has not been submitted to any other journal.
Author contributions
JA-Z designed the study, collected the data, and edited the manuscript. J-MS designed the study and edited the manuscript. JV contributed to statistical analyses, interpretation of data, and manuscript writing. MS interpreted the data, wrote and edited the manuscript. YD collected the data and edited the manuscript. KM contributed to statistical analyses and manuscript editing. OB designed the study, interpreted the data, and wrote and edited the manuscript. All authors approved and accountability for final version of the manuscript.
Acknowledgments
The authors would like to thank Ms. Ingrid Gyselinck, Mr. Momar Diouf, and Mr. Salif Dao for their contribution with data collection.
Conflict of interest
MS and JV were employed by ReSurg SA. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
Al LawatiN. M.PatelS. R.AyasN. T. (2009). Epidemiology, risk factors, and consequences of obstructive sleep apnea and short sleep duration.Prog. Cardiovasc. Dis.51285–293. 10.1016/j.pcad.2008.08.001
2
Ancoli-IsraelS.PalmerB. W.CookeJ. R.Corey-BloomJ.FiorentinoL.NatarajanL.et al (2008). Cognitive effects of treating obstructive sleep apnea in Alzheimer’s disease: a randomized controlled study.J. Am. Geriatr. Soc.562076–2081. 10.1111/j.1532-5415.2008.01934.x
3
AokiK.MatsuoM.TakahashiM.MurakamiJ.AokiY.AokiN.et al (2014). Association of sleep-disordered breathing with decreased cognitive function among patients with dementia.J. Sleep Res.23517–523. 10.1111/jsr.12167
4
ArliB.BilenS.TitizA. P.UlusoyE. K.MunganS.GurkasE.et al (2015). Comparison of cognitive functions between obstructive sleep apnea syndrome and simple snoring patients: OSAS may be a modifiable risk factor for cognitive decline.Appl. Neuropsychol. Adult22282–286. 10.1080/23279095.2014.925901
5
BeebeD. W.GroeszL.WellsC.NicholsA.McGeeK. (2003). The neuropsychological effects of obstructive sleep apnea: a meta-analysis of norm-referenced and case-controlled data.Sleep26298–307. 10.1093/sleep/26.3.298
6
BubuO. M.PirragliaE.AndradeA. G.SharmaR. A.Gimenez-BadiaS.Umasabor-BubuO. Q.et al (2019). Obstructive sleep apnea and longitudinal Alzheimer’s disease biomarker changes.Sleep42:zsz048. 10.1093/sleep/zsz048
7
BucksR. S.OlaitheM.EastwoodP. (2013). Neurocognitive function in obstructive sleep apnoea: a meta-review.Respirology1861–70. 10.1111/j.1440-1843.2012.02255.x
8
ComalliP. E.Jr.WapnerS.WernerH. (1962). Interference effects of Stroop color-word test in childhood, adulthood, and aging.J. Genet. Psychol.10047–53. 10.1080/00221325.1962.10533572
9
CookeJ. R.AyalonL.PalmerB. W.LoredoJ. S.Corey-BloomJ.NatarajanL.et al (2009). Sustained use of CPAP slows deterioration of cognition, sleep, and mood in patients with Alzheimer’s disease and obstructive sleep apnea: a preliminary study.J. Clin. Sleep Med.5305–309.
10
DostalovaV.KoleckarovaS.KuskaM.PretlM.BezdicekO. (2019). Effects of continuous positive airway pressure on neurocognitive and neuropsychiatric function in obstructive sleep apnea.J. Sleep Res.28:e12761. 10.1111/jsr.12761
11
EmamianF.KhazaieH.TahmasianM.LeschzinerG. D.MorrellM. J.HsiungG. Y.et al (2016). The association between obstructive sleep apnea and Alzheimer’s disease: a meta-analysis perspective.Front. Aging Neurosci.8:78. 10.3389/fnagi.2016.00078
12
FreidlW.SchmidtR.StroneggerW. J.FazekasF.ReinhartB. (1996). Sociodemographic predictors and concurrent validity of the mini mental state examination and the mattis dementia rating scale.Eur. Arch. Psychiatry Clin. Neurosci.246317–319. 10.1007/bf02189025
13
FusettiM.FiorettiA. B.ValentiM.MaseduF.LaurielloM.PagliarellaM. (2012). Cardiovascular and metabolic comorbidities in patients with obstructive sleep apnoea syndrome.Acta Otorhinolaryngol. Ital.32320–325.
14
GagnonK.BarilA. A.MontplaisirJ.CarrierJ.ChamiS.GauthierS.et al (2018). Detection of mild cognitive impairment in middle-aged and older adults with obstructive sleep apnoea.Eur. Respir. J.52:1801137. 10.1183/13993003.01137-2018
15
GardnerR.Jr.Oliver-MunozS.FisherL.EmptingL. (1981). Mattis dementia rating scale: internal reliability study using a diffusely impaired population.J. Clin. Neuropsychol.3271–275. 10.1080/01688638108403130
16
GronewoldJ.HaenselR.KleinschnitzC.FrohnhofenH.HermannD. M. (2019). Sleep-disordered breathing in hospitalized geriatric patients with mild dementia and its association with cognition, emotion and mobility.Int. J. Environ. Res. Public Health16:863. 10.3390/ijerph16050863
17
HeinzerR.VatS.Marques-VidalP.Marti-SolerH.AndriesD.TobbackN.et al (2015). Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study.Lancet Respir. Med.3310–318. 10.1016/s2213-2600(15)00043-0
18
HerschE. L. (1979). Development and application of the extended scale for dementia.J. Am. Geriatr. Soc.27348–354. 10.1111/j.1532-5415.1979.tb06056.x
19
HoldenS. K.JonesW. E.BakerK. A.BoersmaI. M.KlugerB. M. (2016). Outcome measures for Parkinson’s disease dementia: a systematic review.Mov. Dis. Clin. Pract.39–18. 10.1002/mdc3.12225
20
HuberP.MulliganR.MackinnonA.Nebuloni-FrenchT.MichelJ. P. (1999). Detecting anxiety and depression in hospitalised elderly patients using a brief inventory.Eur. Psychiatry J. Assoc. Eur. Psychiatr.1411–16. 10.1016/s0924-9338(99)80710-x
21
JorbaI.MenalM. J.TorresM.GozalD.Pinol-RipollG.ColellA.et al (2017). Ageing and chronic intermittent hypoxia mimicking sleep apnea do not modify local brain tissue stiffness in healthy mice.J. Mech. Behav. Biomed. Mater.71106–113. 10.1016/j.jmbbm.2017.03.001
22
Kalafat MichelP. J.Hugonot-DienerL.PoitrenaudJ. (2003). The mini mental state (MMS): French standardization and normative data [Standardisation et étalonnage français du “Mini Mental State” (MMS) version GRÉCO].Rev. Neuropsychol.13209–236.
23
KaszasB.KovacsN.BalasI.KallaiJ.AschermannZ.KerekesZ.et al (2012). Sensitivity and specificity of Addenbrooke’s cognitive examination, mattis dementia rating scale, frontal assessment battery and mini mental state examination for diagnosing dementia in Parkinson’s disease.Parkinsonism Relat. Disord.18553–556. 10.1016/j.parkreldis.2012.02.010
24
KushidaC. A.NicholsD. A.HolmesT. H.QuanS. F.WalshJ. K.GottliebD. J.et al (2012). Effects of continuous positive airway pressure on neurocognitive function in obstructive sleep apnea patients: the apnea positive pressure long-term efficacy study (APPLES).Sleep351593–1602.
25
KuwabaraM.TomitaniN.ShigaT.KarioK. (2018). Polysomnography-derived sleep parameters as a determinant of nocturnal blood pressure profile in patients with obstructive sleep apnea.J. Clin. Hypertens.201039–1048. 10.1111/jch.13308
26
KylstraW. A.AaronsonJ. A.HofmanW. F.SchmandB. A. (2013). Neuropsychological functioning after CPAP treatment in obstructive sleep apnea: a meta-analysis.Sleep Med. Rev.17341–347. 10.1016/j.smrv.2012.09.002
27
LiguoriC.PlacidiF. (2018). Is it time to consider obstructive sleep apnea syndrome a risk factor for Alzheimer’s disease?Am. J. Respir. Crit. Care Med.197855–856. 10.1164/rccm.201710-2105ed
28
MachedaT.RobertsK.LyonsD. N.HigginsE.RitterK. J.LinA. L.et al (2019). Chronic intermittent hypoxia induces robust astrogliosis in an Alzheimer’s disease-relevant mouse model.Neuroscience39855–63. 10.1016/j.neuroscience.2018.11.040
29
MarshallN. S.BarnesM.TravierN.CampbellA. J.PierceR. J.McEvoyR. D.et al (2006). Continuous positive airway pressure reduces daytime sleepiness in mild to moderate obstructive sleep apnoea: a meta-analysis.Thorax61430–434. 10.1136/thx.2005.050583
30
MartinM. S.SforzaE.RocheF.BarthelemyJ. C.Thomas-AnterionC. (2015). Sleep breathing disorders and cognitive function in the elderly: an 8-year follow-up study. the proof-synapse cohort.Sleep38179–187. 10.5665/sleep.4392
31
McKhannG. M.KnopmanD. S.ChertkowH.HymanB. T.JackC. R.Jr.KawasC. H.et al (2011). The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease.Alzheimers Dement. J. Alzheimers Assoc.7263–269. 10.1016/j.jalz.2011.03.005
32
McMorrisT.HaleB. J.BarwoodM.CostelloJ.CorbettJ. (2017). Effect of acute hypoxia on cognition: a systematic review and meta-regression analysis.Neurosci. Biobehav. Rev.74(Pt A), 225–232. 10.1016/j.neubiorev.2017.01.019
33
MenalM. J.JorbaI.TorresM.MontserratJ. M.GozalD.ColellA.et al (2018). Alzheimer’s disease mutant mice exhibit reduced brain tissue stiffness compared to wild-type mice in both normoxia and following intermittent hypoxia mimicking sleep apnea.Front. Neurol.9:1. 10.3389/fneur.2018.00001
34
MontgomeryS. A.AsbergM. (1979). A new depression scale designed to be sensitive to change.Br. J. Psychiatry J. Ment. Sci.134382–389. 10.1192/bjp.134.4.382
35
MoranM.LynchC. A.WalshC.CoenR.CoakleyD.LawlorB. A. (2005). Sleep disturbance in mild to moderate Alzheimer’s disease.Sleep Med.6347–352. 10.1016/j.sleep.2004.12.005
36
MusenG.TinsleyL. J.MarcinkowskiK. A.PoberD.SunJ. K.KhatriM.et al (2018). Cognitive function deficits associated with long-duration type 1 diabetes and vascular complications.Diabetes Care411749–1756. 10.2337/dc17-1955
37
NenaE.SteiropoulosP.PapanasN.TsaraV.FitiliC.FroudarakisM. E.et al (2012). Sleepiness as a marker of glucose deregulation in obstructive sleep apnea.Sleep Breath.16181–186. 10.1007/s11325-010-0472-y
38
OlaitheM.BucksR. S. (2013). Executive dysfunction in OSA before and after treatment: a meta-analysis.Sleep361297–1305. 10.5665/sleep.2950
39
OsorioR. S.GumbT.PirragliaE.VargaA. W.LuS. E.LimJ.et al (2015). Sleep-disordered breathing advances cognitive decline in the elderly.Neurology841964–1971. 10.1212/WNL.0000000000001566
40
PeppardP. E.YoungT.BarnetJ. H.PaltaM.HagenE. W.HlaK. M. (2013). Increased prevalence of sleep-disordered breathing in adults.Am. J. Epidemiol.1771006–1014. 10.1093/aje/kws342
41
PetersenR. C.DoodyR.KurzA.MohsR. C.MorrisJ. C.RabinsP. V.et al (2001). Current concepts in mild cognitive impairment.Arch. Neurol.581985–1992.
42
RenR.LiY.ZhangJ.ZhouJ.SunY.TanL.et al (2016). Obstructive sleep apnea with objective daytime sleepiness is associated with hypertension.Hypertension681264–1270. 10.1161/hypertensionaha.115.06941
43
RichardsK. C.GooneratneN.DiciccoB.HanlonA.MoelterS.OnenF.et al (2019). CPAP adherence may slow 1-year cognitive decline in older adults with mild cognitive impairment and apnea.J. Am. Geriatr. Soc.67558–564. 10.1111/jgs.15758
44
RosenzweigI.GlasserM.PolsekD.LeschzinerG. D.WilliamsS. C.MorrellM. J. (2015). Sleep apnoea and the brain: a complex relationship.Lancet Respir. Med.3404–414. 10.1016/s2213-2600(15)00090-9
45
ShiotaS.TakekawaH.MatsumotoS. E.TakedaK.NurwidyaF.YoshiokaY.et al (2013). Chronic intermittent hypoxia/reoxygenation facilitate amyloid-beta generation in mice.J. Alzheimers Dis.37325–333. 10.3233/JAD-130419
46
SomersV. K.WhiteD. P.AminR.AbrahamW. T.CostaF.CulebrasA.et al (2008). Sleep apnea and cardiovascular disease: an american heart association/American college of cardiology foundation scientific statement from the american heart association council for high blood pressure research professional education committee, council on clinical cardiology, stroke council, and council on cardiovascular nursing. in collaboration with the national heart, lung, and blood institute national center on sleep disorders research (national institutes of health).Circulation1181080–1111. 10.1161/circulationaha.107.189420
47
TroussiereA. C.CharleyC. M.SalleronJ.RichardF.DelbeuckX.DerambureP.et al (2014). Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer’s disease.J. Neurol. Neurosurg. Psychiatry851405–1408. 10.1136/jnnp-2013-307544
48
TsapanouA.VlachosG. S.CosentinoS.GuY.ManlyJ. J.BrickmanA. M.et al (2018). Sleep and subjective cognitive decline in cognitively healthy elderly: results from two cohorts.J. Sleep Res.28:e12759. 10.1111/jsr.12759
49
WallaceA.BucksR. S. (2013). Memory and obstructive sleep apnea: a meta-analysis.Sleep36203–220. 10.5665/sleep.2374
50
World Health Organization [WHO] (2014). C-reactive Protein Concentrations as a Marker of Inflammation or Infection for Interpreting Biomarkers of Micronutrient Status.Geneva: World Health Organization.
51
YaffeK.LaffanA. M.HarrisonS. L.RedlineS.SpiraA. P.EnsrudK. E.et al (2011). Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women.JAMA306613–619. 10.1001/jama.2011.1115
52
YoungT.PaltaM.DempseyJ.SkatrudJ.WeberS.BadrS. (1993). The occurrence of sleep-disordered breathing among middle-aged adults.N. Engl. J. Med.3281230–1235. 10.1056/nejm199304293281704
53
ZhouJ.CamachoM.TangX.KushidaC. A. (2016). A review of neurocognitive function and obstructive sleep apnea with or without daytime sleepiness.Sleep Med.2399–108. 10.1016/j.sleep.2016.02.008
54
ZimmermanM. E.AloiaM. S. (2012). Sleep-disordered breathing and cognition in older adults.Curr. Neurol. Neurosci. Rep.12537–546. 10.1007/s11910-012-0298-z
Summary
Keywords
sleep apnea, cognitive deficit, elderly population, OSAS, CSAS
Citation
Attier-Zmudka J, Sérot J-M, Valluy J, Saffarini M, Douadi Y, Malinowski KP and Balédent O (2020) Sleep Apnea Syndrome in an Elderly Population Admitted to a Geriatric Unit: Prevalence and Effect on Cognitive Function. Front. Aging Neurosci. 11:361. doi: 10.3389/fnagi.2019.00361
Received
26 November 2018
Accepted
10 December 2019
Published
10 January 2020
Volume
11 - 2019
Edited by
Jean Mariani, Université Pierre et Marie Curie, France
Reviewed by
Ricardo Osorio, New York University, United States; Arash Tadjalli, University of Florida, United States
Updates
Copyright
© 2020 Attier-Zmudka, Sérot, Valluy, Saffarini, Douadi, Malinowski and Balédent.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mo Saffarini, journals@resurg.eu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.